Syros Pharmaceuticals Future Growth
Future criteria checks 3/6
Syros Pharmaceuticals is forecast to grow earnings and revenue by 55.5% and 57.1% per annum respectively. EPS is expected to grow by 57.3% per annum. Return on equity is forecast to be 105% in 3 years.
Key information
55.5%
Earnings growth rate
57.3%
EPS growth rate
Biotechs earnings growth | 28.5% |
Revenue growth rate | 57.1% |
Future return on equity | 105.0% |
Analyst coverage | Low |
Last updated | 09 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 151 | -54 | N/A | N/A | 3 |
12/31/2025 | 32 | -120 | N/A | N/A | 5 |
12/31/2024 | 3 | -125 | N/A | N/A | 5 |
12/31/2023 | 10 | -165 | -110 | -110 | N/A |
9/30/2023 | 9 | -105 | -123 | -122 | N/A |
6/30/2023 | 9 | -95 | -127 | -126 | N/A |
3/31/2023 | 12 | -93 | -131 | -130 | N/A |
12/31/2022 | 15 | -95 | -124 | -123 | N/A |
9/30/2022 | 23 | -114 | -116 | -115 | N/A |
6/30/2022 | 25 | -109 | -108 | -107 | N/A |
3/31/2022 | 24 | -97 | -109 | -108 | N/A |
12/31/2021 | 23 | -87 | -101 | -100 | N/A |
9/30/2021 | 21 | -93 | -108 | -106 | N/A |
6/30/2021 | 20 | -86 | -95 | -94 | N/A |
3/31/2021 | 18 | -81 | -81 | -80 | N/A |
12/31/2020 | 15 | -84 | -61 | -57 | N/A |
9/30/2020 | 10 | -74 | -50 | -38 | N/A |
6/30/2020 | 7 | -74 | -48 | -34 | N/A |
3/31/2020 | 4 | -76 | -54 | -40 | N/A |
12/31/2019 | 2 | -75 | -73 | -60 | N/A |
9/30/2019 | 2 | -74 | -68 | -63 | N/A |
6/30/2019 | 2 | -70 | -65 | -62 | N/A |
3/31/2019 | 2 | -64 | -60 | -58 | N/A |
12/31/2018 | 2 | -62 | -42 | -40 | N/A |
9/30/2018 | 1 | -60 | -38 | -37 | N/A |
6/30/2018 | 1 | -58 | -37 | -37 | N/A |
3/31/2018 | 0 | -57 | -35 | -34 | N/A |
12/31/2017 | 1 | -54 | -46 | -45 | N/A |
9/30/2017 | 1 | -50 | N/A | -44 | N/A |
6/30/2017 | 1 | -50 | N/A | -43 | N/A |
3/31/2017 | 1 | -51 | N/A | -43 | N/A |
12/31/2016 | 0 | -51 | N/A | -41 | N/A |
9/30/2016 | N/A | -52 | N/A | -39 | N/A |
6/30/2016 | N/A | -48 | N/A | -35 | N/A |
3/31/2016 | 0 | -41 | N/A | -30 | N/A |
12/31/2015 | 0 | -35 | N/A | -23 | N/A |
9/30/2015 | 0 | -28 | N/A | -18 | N/A |
12/31/2014 | N/A | -16 | N/A | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0LC7 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0LC7 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0LC7 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0LC7's revenue (57.1% per year) is forecast to grow faster than the UK market (3.3% per year).
High Growth Revenue: 0LC7's revenue (57.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0LC7's Return on Equity is forecast to be very high in 3 years time (105%).